Latest Cost Reduction Initiatives News

Coronado Global Resources has filed a detailed SEC Form 8-K revealing confidential discussions with noteholders and outlining its growth trajectory, liquidity management, and operational updates across its Australian and US metallurgical coal assets.

Amaero Ltd reports a remarkable 445% increase in quarterly revenue driven by powder sales and manufacturing scale-up, alongside securing a US$22.8 million loan and exclusive supply agreements with key defense and aerospace players.

Oliver’s Real Food Limited reports a strong September quarter with a 192% EBIT improvement and a positive operating cash flow turnaround, driven by cost efficiencies and strategic store closures.

Orora Limited has finalized its strategic portfolio transformation, delivering solid FY25 financial results despite softness in its glass segment. The company outlines a cautiously optimistic FY26 outlook, underpinned by sustainability progress and investments in beverage packaging innovation.

DGL Group Limited has issued a corrected FY25 financial presentation, revealing lower EBITDA and NPAT figures due to operational challenges and restructuring costs. Despite revenue growth, the company faces a modified audit opinion on inventory and outlines strategic cost-cutting and growth investments.

ClearVue Technologies has announced a comprehensive strategic reset following a Kidder Williams review, including a refreshed board, significant cost savings, and a renewed focus on growth markets in Australia, Asia, and the Middle East.

Coventry Group reports a challenging FY25 with a statutory loss driven by ERP implementation costs and asset impairments, while setting ambitious EBITDA targets for FY26 under refreshed leadership.

AVADA Group Limited reported a revenue decline and a $9.7 million impairment on its New Zealand operations in FY25, while completing Phase 1 of its business transformation including ERP implementation and operational consolidation.

Environmental Clean Technologies Limited reported a $3.52 million net loss for FY2025, marking a modest 5% improvement, while making significant progress in commercialising its COLDry fertiliser technology and securing over $1.7 million in new capital.

DGL Group reported a 4% revenue increase to $481.5 million in FY25, but underlying profits took a hit due to operational losses and restructuring costs. The company is investing heavily in growth and system integration to drive future efficiency.

MedAdvisor reported a 36% revenue drop in FY25, driven by US health program setbacks, and sold its ANZ business to focus on restructuring its US operations.

Percheron Therapeutics posted a 25% increase in net loss for FY2025 amid termination of its Duchenne Muscular Dystrophy programs. The company pivots strategically to oncology with the in-licensing of HMBD-002, a monoclonal antibody targeting VISTA, aiming to initiate Phase II trials in 2026.